Managing patients with advanced and metastatic breast cancer.
Breast cancer is one of the most common cancers in women, and although the prognosis is good for patients with early-stage, localized disease, it is relatively poor for patients with metastatic breast cancer. Treatment options become progressively limited with advancing lines of therapy, primarily because of the development of tumor drug resistance. Nurses have a crucial role in managing patients with breast cancer; therefore, awareness of the clinical efficacy and side-effect profiles of traditional and newer treatment options is of great importance. The taxanes (docetaxel and paclitaxel) are well known for their efficacy in patients with breast cancer. The epothilones, a newer class of microtubule-targeting agents, also are proving beneficial. The most clinically advanced epothilone, ixabepilone, has been approved for the treatment of locally advanced or metastatic disease. Although taxanes and epothilones are similar mechanistically, the epothilones have unique structural, binding, and preclinical properties in terms of microtubule stabilization. Importantly, ixabepilone retains clinical efficacy in patients with metastatic breast cancer who show resistance to taxanes and anthracyclines.
Hurtig
Jane
J
Tennessee Oncology, Nashville, USA. jhurtig@tnonc.com
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis
D000970:Antineoplastic Agents